Healthcare, Pharma & Life Sciences

Trust AI Embeds VELMENI's FDA-Cleared Dental AI Into Isaac Claims Engine

Image
Trust AI Embeds VELMENI's FDA-Cleared Dental AI Into Isaac Claims Engine

San Francisco – – September 12, 2026 -- Trust AI has wired VELMENI's FDA-cleared dental imaging AI directly into its Isaac PracticeOS platform, connecting radiographic diagnosis to a $299-per-month automated claims pipeline that has already recovered months of unbilled revenue at a California practice.

Isaac's agent swarm assembles claims the moment a dentist confirms a VELMENI finding

The integration places VELMENI for DENTISTS (V4D) 2D/3D radiographic analysis inside Isaac's RCM Hub, where automated agents identify payer-specific documentation requirements, select matching billing codes, and attach supporting radiographs before a claim is submitted. Every claim is reviewed by a licensed dentist and a billing specialist before it leaves the system. Trust AI CEO Bernard Casse said the company "wired it into the bloodstream" rather than treating the AI read as a standalone sidebar feature.

Perosphere's ClotChek Coagulometer Validated in Peer-Reviewed DOAC Study

Image
Perosphere's ClotChek Coagulometer Validated in Peer-Reviewed DOAC Study

Danbury, Conn. – September 12, 2026 -- Perosphere Technologies Inc. announced that a clinical study evaluating its ClotChek point-of-care coagulometer has been published in the peer-reviewed journal Thrombosis and Haemostasis, confirming the device's ability to detect anticoagulation levels in patients on Factor Xa inhibitors apixaban and rivaroxaban.

Study confirms ClotChek detects DOAC anticoagulation at two clinical thresholds

The research measured ClotChek Clotting Time (CKCT) against anti-FXa drug levels in patients on direct oral anticoagulants, finding strong correlations when categorized by Medical Decision Limits. The device demonstrated the ability to identify clinically meaningful anticoagulation at both the >75 ng/mL and >30 ng/mL thresholds, including sensitivity at lower drug concentrations.

Eligible Passes SOC 2 Type II With Zero Exceptions

Image
Eligible Passes SOC 2 Type II With Zero Exceptions

New York – September 12, 2026 -- Eligible, Inc. has completed its SOC 2 Type II examination for its Platform Services System with zero exceptions across all four Trust Services Categories evaluated: Security, Availability, Processing Integrity, and Confidentiality.

Independent assessor A-LIGN confirms full compliance across audit period

The examination, conducted by third-party assessor A-LIGN, evaluated the design and operating effectiveness of Eligible's controls over a defined audit period, covering the REST APIs, application infrastructure, and supporting services that process HIPAA-mandated healthcare financial transactions. These include eligibility verification (270/271), claims (837/276/277), remittance (835), and acknowledgements (TA1, 997, 999).

Prezent Vivo Names Alice Choi COO to Scale Life Sciences AI Platform

Image
Prezent Vivo Names Alice Choi COO to Scale Life Sciences AI Platform

Palo Alto, Calif. – September 12, 2026 -- Prezent Vivo, an AI-powered communication platform for the life sciences sector, has appointed Alice Choi as Chief Operating Officer, adding more than 30 years of medical communications experience to its leadership team.

Choi brings three decades of biopharma communications leadership to the role

Choi built her career at organizations including McCann Health and the Omnicom network, holding roles across client services, operations and commercial leadership. She began in academia, earning a master's degree and PhD before moving into medical communications, and has led teams delivering programs for biopharma clients throughout her career.

Pharma CDMO Market to Hit $270.3B by 2031, Wissen Research Says

Image
Pharma CDMO Market to Hit $270.3B by 2031, Wissen Research Says

Sheridan – September 12, 2026 -- The global pharmaceutical contract development and manufacturing organization (CDMO) market is forecast to expand from $191 billion in 2026 to $270.3 billion by 2031, a compound annual growth rate of 7.2%, according to a new study by Wissen Research.

Outsourcing and biologics demand drive the growth trajectory

Pharmaceutical and biotechnology firms are increasingly outsourcing drug development and manufacturing to cut capital costs and refocus internal resources on R&D and commercialization. Demand for biologics, biosimilars, cell and gene therapies, antibody-drug conjugates, and mRNA-based medicines is pushing CDMOs to build specialized manufacturing platforms rather than remain peripheral service providers.

Laboratory Mixers Market to Hit $2.74B by 2031, Says MarketsandMarkets

Image
Laboratory Mixers Market to Hit $2.74B by 2031, Says MarketsandMarkets

Delray Beach, Fla. – September 12, 2026 -- The global laboratory mixers market is projected to reach USD 2.74 billion by 2031, up from USD 2.27 billion in 2026, growing at a compound annual rate of 3.5%, according to a new report from MarketsandMarkets.

Asia Pacific to outpace global growth with 6.5% CAGR

The Asia Pacific region is forecast to grow at a 6.5% CAGR through 2031, outpacing the global average, driven by expanding research laboratory capacity and biopharmaceutical development. North America is expected to retain the largest overall market share in 2031, supported by a dense concentration of research universities, biomedical institutes, contract research organizations, and clinical laboratories that maintain a large installed base of vortex mixers, magnetic stirrers, shakers, and thermal mixers.

Global Medical Supplies Market to Hit $248 Billion by 2031

Image
Global Medical Supplies Market to Hit $248 Billion by 2031

Delray Beach, Fla. – September 12, 2026 -- The global medical supplies market is projected to grow from $194.76 billion in 2026 to $248.03 billion by 2031, a compound annual growth rate of 7.39%, according to new research from MarketsandMarkets.

Asia Pacific outpaces global growth rate as diagnostic demand accelerates

Asia Pacific is set to register the fastest regional CAGR at 10.2% through 2031, outstripping the global average as healthcare infrastructure expands across the region. By product type, infusion and injectable supplies will grow fastest at a 9.0% CAGR, while diagnostic supplies held the largest share in 2025 and are expected to post the quickest growth of any category over the forecast period, driven by rising chronic and infectious disease burdens and expanding preventive screening programs.

Sarcoidosis Drug Pipeline Expands as Efzofitimod Nears Phase 3 Filing

Image
Sarcoidosis Drug Pipeline Expands as Efzofitimod Nears Phase 3 Filing

Las Vegas – – September 12, 2026 -- The sarcoidosis treatment market across the seven major markets is projected to expand steadily through 2036, driven by a pipeline of seven late- and mid-stage drug candidates targeting a disease that affects an estimated 150,000 to 200,000 patients annually in the United States alone, according to a new market report from DelveInsight.

Memorial Healthcare Posts Record $3.8B Revenue, $487.6M Surplus

Image
Memorial Healthcare Posts Record $3.8B Revenue, $487.6M Surplus

Hollywood, Fla. – September 12, 2026 -- Memorial Healthcare System reported $3.8 billion in operating revenue for fiscal year 2026, a 7.7% increase over the prior year, as the South Florida public health system posted its strongest financial results to date.

Operating income surges more than 60% to $220.7 million

Excess of revenues over expenses reached a record $487.6 million, up 20.3% year-over-year. Memorial's net position grew by more than $503 million, closing the fiscal year at $4.1 billion.

Hospital outpatient visits climb 5.7% amid rising patient acuity

Patients increasingly sought advanced specialty care through Memorial's cancer, cardiac, neuroscience and pediatric programs, pushing acuity levels higher across the system.

Natural Field Launches Sleep Complex After 39% Improvement in Preclinical Trial

Image
Natural Field Launches Sleep Complex After 39% Improvement in Preclinical Trial

Shanghai – September 12, 2026 -- Natural Field has expanded its NF TriSolve® nutraceutical solution platform into the sleep wellness category, launching NF TriSolve® SleepRestore Complex after preclinical testing showed a 39% improvement in sleep performance versus a model control group.

Natural Field expands NF TriSolve platform into sleep wellness category

The Shanghai-based nutraceutical ingredient solutions provider built the new formulation by integrating multiple functional components into a single coordinated concept aimed at global nutrition and supplement brands developing differentiated sleep products. The launch follows Natural Field's earlier work on healthy aging and joint wellness solutions under the same branded platform.